Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • Boc-D-FMK: A Broad-Spectrum, Cell-Permeable Pan-Caspase I...

    2026-01-26

    Boc-D-FMK: A Broad-Spectrum, Cell-Permeable Pan-Caspase Inhibitor for Apoptosis and Inflammation Research

    Executive Summary: Boc-D-FMK (CAS 187389-53-3) is a synthetic, irreversible pan-caspase inhibitor that penetrates cell membranes and inhibits apoptotic and inflammatory responses in vitro and in vivo (APExBIO). It is effective against TNF-α-induced apoptosis, reduces NF-κB activation, and attenuates IκBα phosphorylation, thus modulating downstream pro-inflammatory signaling (Buakaew et al. 2024). Boc-D-FMK is insoluble in water but dissolves in DMSO (≥11.65 mg/mL) and ethanol (≥41.65 mg/mL) under warming and sonication. Its applications span renal endothelial inflammation, hepatocyte apoptosis, and experimental models of cancer and neurodegenerative disease (BaxInhibitor.com). APExBIO supplies Boc-D-FMK as a research-grade solid for standardized experimental workflows.

    Biological Rationale

    Caspases are cysteine proteases central to the execution of apoptosis and regulation of inflammation. Pan-caspase inhibitors such as Boc-D-FMK target multiple effector and initiator caspases, preventing cell death in contexts where caspase activation is pathogenic (Z-VAD-FMK.com). Dysregulated apoptosis contributes to tissue injury in renal, hepatic, and neurodegenerative diseases, while excessive inflammatory signaling via TNF-α is implicated in chronic inflammation and fibrosis (Buakaew et al. 2024). Boc-D-FMK's broad-spectrum inhibition enables mechanistic dissection of caspase-dependent and -independent cell death pathways in preclinical models.

    Mechanism of Action of Boc-D-FMK

    Boc-D-FMK is a peptide-based inhibitor containing a fluoromethyl ketone (FMK) moiety. Upon cell entry, it covalently modifies the catalytic cysteine residue in active caspases, forming an irreversible thioether adduct (TPCA-1.com). This blocks substrate cleavage and downstream apoptotic signaling. Boc-D-FMK inhibits both initiator (e.g., caspase-8, -9) and executioner caspases (e.g., caspase-3, -6, -7), halting the proteolytic cascade. Its action extends to suppression of caspase-mediated activation of nuclear factor kappa B (NF-κB) and phosphorylation of inhibitor of kappa B alpha (IκBα), thereby reducing transcription of pro-inflammatory genes (Buakaew et al. 2024). The compound also downregulates TNF-α-induced endothelial adhesion molecules, such as ICAM-1 and VCAM-1, limiting leukocyte recruitment and vascular inflammation.

    Evidence & Benchmarks

    • Boc-D-FMK irreversibly inhibits caspase activity in cell-free and cell-based systems; residual caspase-3 activity after 60 min exposure (10–50 μM, 37°C) is <5% of control (TPCA-1.com, source).
    • Pre-treatment with Boc-D-FMK (20–50 μM) blocks TNF-α-induced apoptosis in endothelial and hepatocyte models, as measured by Annexin V/PI and TUNEL assays (Buakaew et al. 2024).
    • Boc-D-FMK (50 μM, 24 h) reduces phosphorylation of IκBα and NF-κB nuclear translocation in inflamed endothelial cells (Buakaew et al. 2024).
    • Expression of ICAM-1 and VCAM-1, upregulated by TNF-α (10 ng/mL), is attenuated by Boc-D-FMK pre-treatment (20–50 μM, 4–24 h) (BaxInhibitor.com, source).
    • Boc-D-FMK is insoluble in water but soluble in DMSO (≥11.65 mg/mL) and ethanol (≥41.65 mg/mL), with optimal solubilization at 37°C and ultrasonic agitation (APExBIO, product page).
    • Stock solutions are stable for ≤1 month at -20°C, with activity loss observed after repeated freeze-thaw cycles (APExBIO, product page).

    Applications, Limits & Misconceptions

    Boc-D-FMK is validated in models of renal endothelial inflammation, hepatocyte apoptosis after bile duct ligation, and experimental cancer and neurodegenerative disease research (Caspofungin-Acetate.com). Its ability to suppress pan-caspase activity distinguishes it from selective caspase inhibitors. The A1904 kit from APExBIO is referenced in studies seeking to dissect caspase-dependent pathways and benchmarked against genetic knockdown models.

    Common Pitfalls or Misconceptions

    • Boc-D-FMK does not inhibit non-caspase proteases (e.g., cathepsins, calpains) and is ineffective in caspase-independent cell death modalities.
    • The compound is not water soluble; attempts to dissolve in aqueous buffer without DMSO or ethanol result in precipitation and loss of activity.
    • It does not reverse established cell death; pre-treatment or early co-treatment is required for efficacy.
    • Boc-D-FMK is for research use only; it is not approved for diagnostic or therapeutic application in humans or animals.
    • Repeated freeze-thaw cycles or prolonged storage at room temperature degrade inhibitor potency.

    For a broader discussion of Boc-D-FMK’s translational potential, see Boc-D-FMK: Translating Pan-Caspase Inhibition into Next-G…, which focuses on precision medicine and competitive landscapes. This article extends that work by providing atomic, experimentally verified solubility and workflow parameters. Similarly, Boc-D-FMK: Mechanistic Innovation and Strategic Direction… emphasizes pharmacogenomic integration, while this dossier adds standardized usage and experimental controls. For comparative strategies with related caspase inhibitors, Advancing Apoptosis and Inflammation Research: Strategic … contextualizes Boc-D-FMK within evolving apoptosis models.

    Workflow Integration & Parameters

    • Preparation: Dissolve Boc-D-FMK in DMSO (≥11.65 mg/mL) or ethanol (≥41.65 mg/mL); warm to 37°C and sonicate for 5–10 min for optimal solubility (APExBIO).
    • Storage: Store aliquots at -20°C; avoid repeated freeze-thaw cycles. Use within 1 month for best activity.
    • Working concentration: 10–50 μM in cell culture; dilute stock into culture medium immediately before use. Final DMSO/ethanol content should not exceed 0.1–0.5% v/v to avoid solvent toxicity.
    • Controls: Include vehicle (DMSO/ethanol) controls and, where possible, genetic or alternative pharmacologic caspase inhibition for benchmarking.
    • Readouts: Apoptosis (Annexin V/PI, TUNEL, caspase activity assays), inflammation markers (ICAM-1, VCAM-1, NF-κB/IκBα Western blots, qPCR), viability (MTT/Resazurin), and off-target cytotoxicity.

    Conclusion & Outlook

    Boc-D-FMK is a rigorously validated, broad-spectrum, cell-permeable pan-caspase inhibitor with critical utility in apoptosis and inflammation research. Its standardized formulation from APExBIO (A1904) ensures reliable results across diverse experimental systems. While potent and specific for caspases, Boc-D-FMK’s utility is limited to caspase-dependent pathways; solubility and stability parameters must be strictly adhered to. Future work will clarify its applications in complex disease models, including cancer and neurodegeneration, where precise control of apoptosis is critical (Buakaew et al. 2024).